Inclusion Criteria:

- Histologically or cytologically confirmed NSCLC stage IIIb with malignant pleural
effusion or stage IV

- Pulmonary primary tumor or at least one NSCLC metastasis in the lung measuring at
least 1 cm in diameter and eligible for local radiation with 20 Gy

- Disease control (partial remission or stable disease) after 4 cycles of
platinum-based first-line chemotherapy whereby the time between the last dose of
first-line chemotherapy and start of trial treatment should not be longer than 8
weeks

- Male or female, aged ≥18 years of age

- Signed written informed consent

- Effective contraception for male and female subjects of childbearing age

- ECOG performance status 0 or 1

- Adequate hematological function defined by WBC ≥3 x 10^9/L, neutrophils ≥1.5 x
10^9/L, lymphocyte count ≥0.5 x 10^9/L, platelet count ≥100 x 10^9/L; hemoglobin ≥9
g/dL

- Estimated creatinine clearance ≥50 mL/min according to the Cockcroft - Gault formula
or 24-h urine sampling

- Adequate hepatic function defined by a total bilirubin level ≤1.5 times the upper
limit of normal (ULN), and aspartate aminotransferase (AST) and alanine
aminotrasferase (ALT) ≤5 x ULN

Exclusion Criteria:

- Requirement for immunosuppressive treatment with the exception of inhalative
corticosteroids or low-dose systemic corticosteroids (prednisone equivalent dose ≤10
mg/day)

- Systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis)

- Organ transplant recipients

- Active infections (including HIV, hepatitis B and C, tuberculosis)

- Known or clinically suspected brain metastases

- Active cardiovascular/cerebrovascular disease (e.g. symptomatic coronary vascular
disease, congestive heart failure ≥ NYHA II, LVEF <50%, ventricular arrhythmia
requiring medication, myocardial infarction or stroke) within previous 6 months

- Pericardial effusion

- Major impairment in pulmonary function: forced expir¬atory volume in 1 second (FEV1)
<50% and diffusion capacity for carbon monoxide (DLCO) <50% of normal limit

- Any other significant disease that in the Investigator's opinion would exclude the
subject from the trial

- Known conditions associated with necroses of non-tumor bearing tissues (e.g.
esophageal or gastroduodenal ulcers, ischemic bowel disease, chronic inflammations)

- Pregnancy or lactation

- Radiotherapy, chemotherapy, major surgery, biological therapy or any investigational
drug within 30 days prior to the start of trial treatment

- Requirement for concurrent systemic anticancer treatment (chemotherapy, biological
therapy)

- Pretreatment with anti-EGFR antibodies or tyrosine kinase inhibitors

- Participation in another interventional clinical trial within the past 30 days before
start of trial treatment

- Known alcohol or drug abuse

- Any psychiatric condition that would prohibit the understanding or rendering of the
informed consent

- Legal incapacity or limited legal capacity